Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data

@article{Gallwitz2006ExenatideIT,
  title={Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data},
  author={B. Gallwitz},
  journal={International Journal of Clinical Practice},
  year={2006},
  volume={60}
}
  • B. Gallwitz
  • Published 2006
  • Medicine
  • International Journal of Clinical Practice
The therapeutic options for treating type 2 diabetes have been widened by the introduction of exenatide as the first incretin mimetic. Incretins are gut hormones that contribute to the stimulation of insulin secretion after a carbohydrate rich meal. The incretin hormone glucagon‐like peptide‐1 (GLP‐1) not only stimulates insulin secretion under hyperglycaemic conditions, but also suppresses glucagon secretion, slows gastric emptying, induces satiety and improves beta cell function in type 2… Expand
Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus
Glucagon-like Peptide-1 Analogues for Type 2 Diabetes Mellitus
Incretin-based Therapies for Type 2 Diabetes.
Exenatide: incretin therapy for patients with Type 2 diabetes mellitus
Exenatide
The evolving place of incretin-based therapies in type 2 diabetes
GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
  • B. Gallwitz
  • Medicine
  • Handbook of experimental pharmacology
  • 2011
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Entero-insular axis and diabetes mellitus.
  • W. Creutzfeldt
  • Medicine
  • Hormone and metabolic research. Supplement series
  • 1992
Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.
...
1
2
3
4
...